AGN-1135
 | This article may be too technical for most readers to understand. (September 2024) |
 | |
| Clinical data | |
|---|---|
| Other names | AGN-1135; Racemic rasagiline; (±)-Rasagiline; (RS)-Rasagiline; N-Propargyl-1-aminoindane |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H13N |
| Molar mass | 171.243 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1][2] It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022).[1][2] Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor.[1] Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer.[1] In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.[1]
See also
[edit]- Deprenyl (the racemic form of selegiline)
- SU-11739 (the racemic N-methyl analogue of rasagiline)
- Desmethylselegiline (DMS; the N-demethylated analogue of selegiline)
References
[edit]- ^ a b c d e Finberg JP (February 2020). "The discovery and development of rasagiline as a new anti-Parkinson medication". Journal of Neural Transmission. 127 (2): 125–130. doi:10.1007/s00702-020-02142-w. PMID 31974721.
- ^ a b Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |